By Reed Richardson

It is well known, poor medication adherence is an exponentially growing problem. Approximately 50% of patients do not take their medications as prescribed, even more relevant in patients with chronic conditions, as the number of prescribed medications continues to grow. This issue is linked to increased healthcare costs, morbidity, and mortality. In the US, interventions such as personalized medicine may be necessary to increase patient medication adherence. One intervention may include incorporating pharmacogenomic (PGx) testing into daily clinical care, with treatment options being tailored to the patient. 

Multiple factors lead to a patient’s medication non-adherence, a few of these include increased concern for side effects, efficacy, cost, and having the ability to play an active role in deciding his or hers medication treatments. It is important to increase a patient’s trust in the medication therapy, which includes safety and efficacy, two important aspects covered by PGx testing. Allowing the patient to play an active role, increasing their knowledge about treatment options incorporating PGx testing results, has shown to increase medication adherence. In addition, the likelihood the patient will initiate therapy and continue to adhere to their medication regimen is increased due to increased confidence in their prescriber, knowing they have taken into all of these considerations when choosing the patient’s treatment. 

PGx testing has been associated with increased adherence and clinical outcomes. Knowledge of knowing your own genetic makeup and medication therapies have been chosen based on this information along with family history, past medications, lab results, and allergies, will not only improve clinical outcomes but also the patient’s adherence, knowing prescribed medications were based on them and their history. This then allows a patient to have the right medication at the right dose the first time, driving down costs to the patient and the health system, improving short-and long-term outcomes. 

The creation of hc1 PGx Advisor™ allows for individualized dosing, increased efficacy, maximized safety and overall higher patient satisfaction resulting in less non-adherence. As a clinician utilizes hc1 PGx Advisor, they are able to combine the patient’s PGx results with other key pieces of information such as lifestyle, family history, medical history, allergies, and past medications in order to determine the right drug and right dose for the patient. In addition, clinicians are able to see how a patient’s risk score may change between the patient’s current and potential, new medication regimen after all the variables are taken into consideration. 

Subscribe to the blog
Previous Post hfma Features Automated Clinical Decision Support
Next Post FDA Directs New Opioid Labeling